Can antibody-drug conjugates bypass multidrug resistance of cancer cells?

Michael Firer, G. Luboshits

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Drug resistance in cancer cells remains a significant hurdle
to successful chemotherapy of cancer patients. Despite
the development of new drugs designed to interfere with
the unique biology of cancer cells, the common outcome
of chemotherapy is the outgrowth of malignant clones
resistant to drug action. Targeted drug delivery (TDD) systems,
exemplified by antibody–drug conjugates (ADC),
deliver their payloads through a pathway that should
bypass drug resistance mechanisms. In this chapter we
review the evidence for this possibility and find that ADCs
can bypass drug resistance and kill tumor cells. ADC efficacy
depends on the type of targeting antibody used,
conjugation chemistry and the chemical nature of the
drug. With these considerations in place, the near future
should see the development of evenmore clinically effective
Original languageEnglish
Title of host publicationOptimizing antibody-drug conjugates for targeted delivery of therapeutics
EditorsNorbert Sewald
Place of PublicationLondon
PublisherFuture Science
Number of pages13
ISBN (Print)9781910419359
StatePublished - Dec 2015


Dive into the research topics of 'Can antibody-drug conjugates bypass multidrug resistance of cancer cells?'. Together they form a unique fingerprint.

Cite this